

Pioneering the Science of Time

COMPANY OVERVIEW APRIL 14, 2022



Forward-looking statements

This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words "aim," "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forwardlooking statements contain these identifying words. In this presentation, forward-looking statements include, without limitation, express or implied statements regarding plans, strategies, and trug candidates of Blueprint Medicines Corporation (the "Company"), including timelines for the initiation of clinical trials, data publications, marketing applications and approvals; the anticipated benefits of the Company's ISM Symptom Assessment Form; expectations related to the expansion of the Company's research platform; the Company's plans, strategies and timelines to increase output from its discovery engine and to nominate development the anticipated benefits of the preclinical profiles of the Company's drug candidates; the Company's plans, strategies and timelines for the development of the Company's drug candidates as monotherapies and combination with other agents; anticipated indications for the Company's drug candidates; plans, and timelines for avapritinib and pralsetinib and, if approved, commercialization of avapritinib and pralsetinib in additional indications or in additional geographies; the potential benefits of the Company's current or future approved drugs or drug candidates in treating patients; and the Company's financial performance, strategy, goals and anticipated milestones, business plans and focus.

The Company has based these forward-looking statements on management's current expectations, assumptions, estimates and projections. If such expectations, assumptions, estimates and projections do not fully materialize or prove incorrect, the events or circumstances referred to in the forward-looking statements may not occur. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks, uncertainties and other important factors, many of which are bevond the Company's control and may cause actual results, performance or achievements to differ materially from those expressed or implied by any forward-looking statements. These risks and uncertainties include, without limitation, risks and uncertainties related to the impact of the COVID-19 pandemic to the Company's business, operations, strategy, goals and anticipated milestones, including the Company's ongoing and planned research and discovery activities, ability to conduct ongoing and planned clinical trials, clinical supply of current or future drug candidates, commercial supply of current or future approved drugs, and launching, marketing and selling current or future approved drugs; the Company's ability and plans in establishing a commercial infrastructure, and successfully launching, marketing and selling current or future approved products; the Company's ability to successfully expand the approved indications for AYVAKIT® (Avapritinib) and GAVRETO® (pralsetinib) or obtain marketing approval for AYVAKIT/AYVAKYT in additional geographies in the future: the delay of any current or planned clinical trials or the development of the Company's drug candidates or the licensed drug candidate; the Company's advancement of multiple early-stage efforts; the Company's ability to successfully demonstrate the efficacy and safety of its drug candidates and gain approval of its drug candidates on a timely basis, if at all: the timing and results of preclinical and clinical studies for the Company's drug candidates, which may not support further development of such drug candidates either as monotherapies or in combination with other agents or may impact the anticipated timing of data or regulatory submissions; actions or decisions of regulatory agencies or authorities, which may affect the initiation, timing and progress of clinical trials or marketing applications; the Company's ability to obtain, maintain and enforce patent and other intellectual property protection for AYVAKIT/AYVAKYT, GAVRETO or any drug candidates it is developing; the Company's ability to develop and commercialize companion diagnostic tests for any of the Company's current or future approved drugs or drug candidates; the Company's ability to successfully expand its operations and scientific platform and the costs thereof; the Company's ability to realize the benefits of its executive leadership transition plan; and the success of the Company's current and future collaborations, partnerships and licenses. These and other risks and uncertainties are described in greater detail under "Risk Factors" in the Company's filings with the Securities and Exchange Commission ("SEC"), including its most recent Annual Report on Form 10-K, as supplemented by its most recent Quarterly Report on Form 10-Q, and any other filings it has made or may make with the SEC in the future. The Company cannot guarantee future results, outcomes, levels of activity. performance, developments, or achievements, and there can be no assurance that its expectations, intentions, anticipations, beliefs, or projections will result or be achieved or accomplished. The forward-looking statements in this presentation are made only as of the date hereof, and except as required by law, the Company undertakes no obligation to update any forward-looking statements contained in this presentation as a result of new information, future events or otherwise. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements.

This presentation also contains estimates, projections and other statistical data made by independent parties and by the Company relating to market size and growth and other data about the Company's industry. These data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of the Company's future performance and the future performance of the markets in which the Company operates are necessarily subject to a high degree of uncertainty and risk.



Blueprint Medicines, AYVAKIT, AYVAKYT, GAVRETO and associated logos are trademarks of Blueprint Medicines Corporation.

Blueprint Medicines is a global leader in precision therapy





Ongoing global collaboration with Roche and Genentech for the development and commercialization of GAVRETO

OUR FIRST DECADE OF ACHIEVEMENT 2 internally discovered medicines FDA & EMA approved across 5 indications within 10 years, and with 5 breakthrough therapy designations

BROAD AND GROWING PORTFOLIO WITH 10 PRECISION THERAPIES IN DEVELOPMENT



AVVAKIT is approved for the treatment of adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations, and adult patients with advanced SM, including aggressive SM, SM with an associated hematologic neoplasm and mast cell leukemia. GAVPETO is approved for the treatment of adult patients with RET-fusion positive NSCLC, adult and pediatric patients with advanced or metastatic RET mutant medullary thyroid cancer who require systemic therapy and adult, and pediatric patients with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and adult, and pediatric patients with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory. FDA, U.S. Food and Drug Administration; GIST, gastrointestinal stromal tumor; NSCLC, non-small cell lung cancer; SM, systemic mastocytosis. Not for promotional use.

Our path to potential transformative growth and an independent financial profile

YEAR END 2021

- AYVAKIT/AYVAKYT and GAVRETO approved with ongoing global expansion
- A leading precision therapy research platform
- Strong financial position with ~\$1B cash and cash equivalents

NEAR-TERM PLANS • 2022-2023

- Constellation of clinical data catalysts
 across strategic therapeutic areas
- AYVAKIT launch in non-advanced systemic mastocytosis
- Continued product revenue growth plus collaboration milestones and royalties

FUTURE GOALS • 2024-2025+

- Broad portfolio of marketed medicines in precision oncology and hematology
- Diversified research platform with unparalleled productivity
- Independent financial profile



Our path to potential transformative growth and an independent financial profile

YEAR END 2021

- AYVAKIT/AYVAKYT and GAVRETO approved with ongoing global expansion
- A leading precision therapy research platform
- Strong financial position with ~\$1B cash and cash equivalents

PLANS • 2022-2023

of clinical data catalysts ic therapeutic areas

ich in non-advanced ocytosis

duct revenue growth plus nilestones and royalties

UTURE GOALS • 2024-2025


- Broad portfolio of marketed medicines in precision oncology and hematology
- Diversified research platform with unparalleled productivity
- Independent financial profile



Not for promotional use.

5

AYVAKIT update: full-year and Q4 2021 performance




ANTICIPATE \$115 TO \$130 MILLION IN AYVAKIT NET PRODUCT REVENUES IN 2022




1. Reported data represent estimations. QoQ, quarter over quarter.

Using innovative data-driven approaches to optimize engagement


OBSERVED MONTHLY SM DIAGNOSES IN U.S.¹



REAL-TIME PROVIDER ENGAGEMENT FOR ADVANCED SM²



likely diagnoses



Moving average



1. Based on analyses of available U.S. claims data. 2. Healthcare provider targeting exclusively focused on AYVAKIT's FDA approved indication for advanced SM.

Upcoming wave of clinical data BLU-222: Breast, ovarian and other milestones has the potential to cyclin E-CDK2 aberrant cancers dramatically expand our impact BLU-945 / BLU-701 / BLU-451: EGFR+ NSCLC AYVAKIT / BLU-263: Non-advanced SM AYVAKIT: Advanced SM GAVRETO: RET+ NSCLC and thyroid cancer AYVAKIT: PDGFRA exon 18 mutant GIST

TIMING OF DATA CATALYSTS



Figure is illustrative. GIST, gastrointestinal stromal tumors; NSCLC, non-small cell lung cancer.

Our path to potential transformative growth and an independent financial profile

YEAR END 202

- AYVAKIT/AYVAKYT and GAVRET approved with ongoing global expa
- A leading precision therapy researce platform
- Strong financial position with ~\$1B and cash equivalents

NEAR-TERM PLANS • 2022-2023

- Constellation of clinical data catalysts across strategic therapeutic areas
- AYVAKIT launch in non-advanced systemic mastocytosis
- Continued product revenue growth plus collaboration milestones and royalties

UTURE GOALS • 2024-2025

ad portfolio of marketed medicines recision oncology and hematology

ersified research platform with paralleled productivity

ependent financial profile



Not for promotional use.

9

SYSTEMIC MASTOCYTOSIS STRATEGIC THERAPEUTIC AREA

Pioneering the Science of Time


Every day, we seek to transform science into more time for life. Time to be with families, time to be productive community members, time to feel the small moments of joy that shape our lives.





Systemic mastocytosis, a rare mast cell disease with high medical need

SYSTEMIC MASTOCYTOSIS SYMPTOMS



95% of SM cases driven by the KIT D816V mutation

ADVANCED SM¹

6 months to 3.5 years median overall survival based on disease subtype


NON-ADVANCED SM²

30% had ≥1 emergency room visit in prior year
51% take ≥3 prescription medicines for SM
65% reported SM impacted their ability to work
90% feel SM controls their life to some extent
Worse physical functioning and mental health reported than patients with colorectal or lung cancer



1. Sperr WR, et al. Lancet Haematol, 2019. 2. Data from the TouchStone Survey presented at American Society of Hematology annual meeting in December 2020.

Avapritinib is a clinically validated, highly potent inhibitor of KIT D816V



Safety data support evaluation of chronic treatment



-80

1. Top-line EXPLORER and PATHFINDER data reported in September 2020. Data cutoff: May 27, 2020 for EXPLORER and June 23, 2020 for PATHFINDER, with response assessments per central review completed in September 2020. 2. Data reported at AAAAI Annual Meeting in March 2020. Data cutoff: December 27, 2019.

Broad clinical strategy designed to address the spectrum of medical need in non-advanced SM

Avapritinib

 FDA breakthrough therapy designation granted for moderate to severe indolent SM

PIONEER

Phase 2 trial in non-advanced SM




Plan to report top-line registration-enabling Part 2 data in mid-2022

BLU-263

- Next-generation KIT D816V inhibitor
- Opportunity to reach a broader population of patients with SM, based on potential for optimized risk-benefit profile



Phase 2/3 trial in non-advanced SM



Plan to present data in 2H 2022



ISM-SAF, indolent SM symptom assessment form; RP2D, recommended part 2 dose; TSS, total symptom score.

ISM-SAF is a patient-reported outcomes tool developed with input from SM patients, disease experts and global regulatory authorities

ISM-Symptom Assessment Form

- Clinical benefit measure and primary endpoint for PIONEER trial
- Designed with input from disease experts, patients and regulatory authorities to support regulatory approval¹
- ISM-SAF produced reliable, construct-valid, sensitive scores when administered in PIONEER Part 1 to patients with indolent SM²

Symptom	Domains	Score			
Abdominal pain	GI				
Diarrhea	(0 - 30)				
Nausea		Scored 0 – 10			
Spots	_	daily (24-hour recall) on a handheld device			
Itching	Skin (0 – 30)				
Flushing	(0 - 30)	0 is no symptoms			
Brain Fog		10 is worst			
Headache	Neurocognitive (0 – 30)	Analyzed as a 14-day moving average			
Dizziness					
Bone pain					
Fatigue					

Total Symptom Score (0-110)



1. Taylor, et al. Orphanet J Rare Dis, 2021. 2. Padilla, et al. Orphanet J Rare Dis, 2021. Gl, gastrointestinal.

CLINICALLY IMPORTANT TSS OUTCOMES

~30% reduction in ISM-SAF TSS


- 30% reduction in TSS is correlated with 1 to 2-point change on PGIS symptom questionnaire¹
- 2-point reduction on PGIS is associated with change from severe to mild symptoms²

~30% difference in ORR versus placebo

 Registration-enabling symptom assessment tools have shown ORR differences of ~15-40% versus placebo (e.g., linaclotide, ruxolitinib)²

PIONEER PART 1 DATA SHOW TSS CORRELATES WITH MC-QOL³

mean % change from baseline in TSS and MC-QoL - Ava group vs Placebo






1. Padilla, et al. Orphanet J Rare Dis, 2021. 2. Linaclotide and ruxolitinib prescribing information. 3. Data reported at AAAAI annual meeting in March 2020. Data cutoff: December 27, 2019. PGIS, Patient Global Impression of Symptom Severity; ORR, overall response rate.

Significant initial target SM patient population, with high growth potential

75,000 SM PATIENTS IN MAJOR MARKETS

5-10% ADVANCED SM

90-95% NON-ADVANCED SM





Major markets include U.S., France, Germany, Italy, Spain, the United Kingdom and Japan. Cohen S et al Br J Haematol (2014) 166(4):521-8 and World Bank Population data. Reported data represent estimations only.

We're executing a comprehensive plan to accelerate SM patient identification

RAISE AWARENESS VIA EDUCATION

 Multiple ongoing healthcare provider and patient education programs designed to unmask signs and symptoms of disease

SUPPORT ACCESS TO TESTING

 Sponsored no-charge KIT D816V testing program with LabCorp Oncology now available for patients with suspected SM

GENERATE EVIDENCE

 PROSPECTOR screening study initiated to assess KIT D816V prevalence in patients with evidence of mast cell activation

ENHANCE TESTING INFRASTRUCTURE

- Highly sensitive blood-based KIT D816V testing is recommended and available at laboratories covering >80% of SM patients
- Ongoing community engagement to generate testing and treatment algorithms



LUNG CANCER STRATEGIC THERAPEUTIC AREA


Precision that Moves

We help patients stay one step ahead with therapies that adapt to disease evolution. This includes solving for treatment resistance and intractable sites of progression, as well as pioneering innovative combinations to prolong benefit.






Increasing tumor resistance and complexity drives disease progression, with no approved therapies after 1L standard of care osimertinib





Approximate patient numbers covering major markets – US, EU4, UK, and Japan. 1. Excludes rare mutations including exon 20 insertions. Internal estimates adapted from Ramalingam, et al. NEJM, 2020; Decision Resources Group: NSCLC Forecast and Epidemiology; and Harrison Seminars in Cancer Biology, 2020. Ex19del, exon 19 deletion mutations; CNS, central nervous system; OS, overall survival; PFS, progression free survival. **Not for promotional use.**

Opportunities for our next-generation EGFR precision therapies






Approximate patient numbers covering major markets – US, EU4, UK, and Japan. 1. Excludes rare mutations including exon 20 insertions. Internal estimates adapted from Ramalingam, et al. NEJM, 2020; Decision Resources Group: NSCLC Forecast and Epidemiology; and Harrison Seminars in Cancer Biology, 2020. CNS, central nervous system. Not for promotional use.

Our portfolio of EGFR therapies are purpose-built to address medical needs

BLUEPRINT MEDICINES EGFR PORTFOLIO



CS, C797S resistance mutation; Ex20in, activating exon 20 insertion mutations; LR, L858R activating mutation; TM, T790M resistance mutation

Early BLU-945 dose escalation data achieve clinical proof-of-concept



Dose-dependent reductions in ctDNA allele fractions for EGFR resistance mutations targeted by BLU-945



Increasing coverage of EGFR activating and resistance mutations at higher doses, based on pharmacokinetic data



Dose-dependent antitumor activity, with reductions in target lesions observed at 200 mg QD and higher




Generally well-tolerated, with no significant adverse events associated with wild-type EGFR inhibition

DATA SUPPORT INITIATION OF BROAD COMBINATION DEVELOPMENT STRATEGY




BLU-945 treatment led to dose-dependent reductions in ctDNA

83% OF EGFR-T790M VARIANT ALLELES REDUCED WITH TREATMENT



81% OF EGFR-C797S VARIANT ALLELES REDUCED WITH TREATMENT




• In the 400-mg cohort, all detectable T790M and C797S alleles showed reduction, including three that fell below the limit of detection (clearance)



Data presented at AACR in April 2022. ^aPatient had two different DNA mutations in C797S. Note: reductions in individual variant allele fractions as shown; therefore, patients with multiple mutations may be represented on both plots. All T790M and C797S allele fractions with available baseline and C1D15 data are shown. Increases of greater than 100% were truncated at 100%. C, Cycle; ctDNA, circulating tumor DNA; D, day; F1LCDx, FoundationOne Liquid CDx assay; QD, once daily.1. Ku BM et al. Oncology. 2022; Epub ahead of print. PMID: 35196661; 2 Ma L et al. Front Oncol. 2021;11:643199; 3. Fernandes MGO et al. Cells. 2021;10:1912. As of the data cut-off (March 9, 2022), 33 patients have been treated with BLU-945 at 25–400 mg once daily (QD) in the first 5 cohorts.

23

BLU-945 showed dose-dependent anti-tumor activity, with tumor shrinkage reported at doses ≥200 mg QD



- Unconfirmed PR reported in patient with ex19del/T790M/C797S treated at 400 mg QD
- Dose escalation from 100 to 200 mg QD led to stabilization of tumor growth in two patients

Not for promotional use.

Data presented at AACR in April 2022.

^aPatients with measurable target lesions at baseline with post-baseline scans (investigator assessed); ^bData cut off, March 9, 2022; CR, complete remission; EOT, end of treatment; PD, progressive disease; PR, partial remission; QD, once daily; SD, stable disease. An unconfirmed PR is a PR in which tumor reduction ≥30% has occurred but has not yet been confirmed via a subsequent scan. As of the data cut-off (March 9, 2022), 33 patients have been treated with BLU-945 at 25–400 mg once daily (QD) in the first 5 cohorts.

BLU-945 was generally well-tolerated in the ongoing Phase 1 trial

AEs, regardless of		AEs :33	Treatment-related AEs N=33		
causality, n (%)	Any grade	Grade 3	Any grade	Grade 3	
Nausea	10 (30)	2 (6)	7 (21)	1 (3)	
Headache	6 (18)	2 (6)	1 (3)	0	
Fatigue	6 (18)	0	5 (15)	0	
Cough	5 (15)	0	1 (3)	0	
Dyspnea	5 (15)	1 (3)	0	0	
Vomiting	5 (15)	1 (3)	3 (9)	1 (3)	
Hyponatremia	4 (12)	0	0	0	
Dry Mouth	4 (12)	0	3 (9)	0	
Anemia	4 (12)	1 (3)	0	0	

Most common AEs by preferred term in ≥10% of patients


- No Grade 4 or 5 AEs
- One DLT, grade 3 transaminitis, in 400 mg QD cohort
 - Improved with dose interruption; patient remains on therapy
- · AEs associated with EGFR wild-type inhibition were minimal
- No interstitial lung disease or QTc prolongation
- 8 (24%) serious AEs, with 2 (6%) deemed to be related:
 - Grade 3 vomiting
 - Grade 3 transaminitis
- No treatment discontinuations due to AEs
- Dose escalation continues and the MTD has not yet been determined



Data presented at AACR in April 2022. AE, adverse event; DLT, dose-limiting toxicity; MTD, maximum tolerated dose. As of the data cutoff (March 9, 2022), 33 patients have been treated with BLU-945 at 25–400 mg once daily (QD) in the first 5 cohorts.

25

Phase 1/2 trials to rapidly generate data in broad populations, informing development and registration strategies



PLANNED INITIATION OF PHASE 1/2 SYMPHONY / HARMONY TRIAL COHORTS





Potent inhibition of all common EGFR exon 20 insertion variants



CNS penetrant with robust activity in a preclinical intracranial model



Highly selective over wild-type EGFR and off-target kinases



Oral administration, with well-characterized preclinical pharmacology

BLU-451 PRECLINICAL PROFILE HAS POTENTIAL TO TRANSLATE INTO IMPROVED SAFETY AND EFFICACY, INCLUDING IN PATIENTS WITH BRAIN METASTASES




Preclinical data show BLU-451 is highly selective, potent and CNS penetrant

HIGHLY SELECTIVE OVER WILD-TYPE EGFR (CELLULAR ACTIVITY IC50, NM)

		BLU-451
	WT EGFR	1,630
	01/2	50
ts	SVD	53
ariar	ASV	78
	NPH	75
insertion variants	FQEA	61
'.⊆		_

7

ROBUST ANTI-TUMOR ACTIVITY IN AN EGFR EXON 20 MODEL



HIGHLY CNS PENETRANT

PRECLINICAL DATA PRESENTED FOR BLU-451 AT AACR ANNUAL MEETING



NPG

EGFR Exon 20

Lengo Therapeutics data on file. WT EGFR lines comprise A431, H2073, and Ba/F3 WT EGFR cells. In vivo efficacy demonstrated in LU0387 PDX model.

ADDITIONAL PIPELINE PROGRAMS


The Urgency of Now

We are constantly on the move, relentless in our determination to accelerate development of new therapies, expedite clinical trials and quickly bring approved medicines to patients worldwide.





CDK2 and CCNE1 are cell cycle regulators implicated in various CDK2vulnerable cancers



Aberrant CCNE hyperactivates CDK2, dysregulating Rb protein phosphorylation and E2F transcription factor activation of S-phase genes, resulting in cancer cell proliferation




E2F, E2F transcription factor; P, phosphorylation; Rb, retinoblastoma protein.

Aberrant CCNE is a disease driver in multiple cancers

LOWER PFS IN PALBOCICLIB-TREATED HR+ BREAST CANCER WITH HIGH CCNE1²

REPRESENTATIVE TUMOR TYPES BY CCNE1 AMPLIFICATION FREQUENCY¹





1. CCNE1 amplification frequency represented as percentage of total patient samples. Data from the National Cancer Institute's The Cancer Genome Atlas Program (www.cancer.gov/tcga). 2. Turner, et al. Cyclin E1 expression and palbociclib efficacy in previously treated hormone receptor-positive metastatic breast cancer. J Clin Oncol, 2019.

BLU-222 is a selective and potent CDK2 inhibitor

	Enzyme activity IC ₅₀ (nM) ^b							Cellular activity IC ₅₀ (nM) ^d	
Kinome S(10)ª	CDK2	CDK1	CDK4	CDK6	CDK7	CDK9		pRb T821 (CDK2 cell)	pLamin S22 (CDK1 cell)
0.045	2.6	233.6	377.4	275.2	6941.2	6115.1		4.2	380.2
		NanoB	RET acti	vity IC ₅₀	(nM)°				
	CDK2	CDK1	CDK4	CDK6	CDK7	CDK9			
	17.7	452.3	5104.6	2621.7	6330.4	2697.7			


BLU-222 EXHIBITS SINGLE-DIGIT NANOMOLAR POTENCY AND IS SELECTIVE FOR CDK2 OVER OTHER CDK FAMILY MEMBERS

Data presented at AACR 2022 Annual Meeting.



^aKinome S(10): fraction of kinases with <10 percentage of control at 3 uM among all the kinases tested, measured by KINOME scan platform against 468 kinases. ^bEnzyme activities IC₅₀ were measured at 1 mM ATP using canonical CDK/Cyclin pairs: CDK2/Cyclin E1; CDK1/Cyclin B1; CDK4/Cyclin D3; CDK6/Cyclin D3; CDK7/Cyclin H1/MNAT1; CDK9/Cyclin T1. ^cHEK-293T cells were transfected with canonical CDK/cyclin pairs as in the enzyme assay and treated with compound and a tracer for 2 hours before measurements were taken. ^dPRb T821 protein was assessed in synchronized OVCAR-3 cells to reflect CDK2 cellular potency; pLamin S22 was assessed in asynchronous OVCAR-3 cells to reflect CDK1 cellular potency. ATP, adenosine triphosphate; IC₆₀, half-maximal inhibitory concentration; pRB, phosphorylated retinoblastoma protein.

Phase 1/2 VELA trial of BLU-222 advancing toward clinical proof-of-concept




PHASE 1/2 VELA TRIAL OF BLU-222 INITIATED IN Q1 2022 AND FIRST PATIENT DOSED



CCNE1, cyclin E; CDK4/6i, CDK4/6 inhibitor; ER, estrogen receptor.

Research platform expansion to drive innovation & expanded productivity




EXPANSION AIMS TO DOUBLE THE HISTORIC OUTPUT OF OUR DISCOVERY ENGINE BY 2025



Significant progress across our portfolio will drive near-term news flow







Top-line PIONEER trial data in non-advanced SM with potential to significantly expand AYVAKIT label Multiple anticipated datasets for EGFR and CDK2 programs with potential to unlock broad patient opportunities Plan to unveil new research programs and vision for scientific platform expansion at R&D Day

MID-2022

2H 2022 THRU 2023

2H 2022



		DISCOVERY	EARLY-STAGE DEVELOPMENT	LATE-STAGE DEVELOPMENT	REGULATORY SUBMISSION	APPROVED
Hematologic disorders	AYVAKIT® (avapritinib): KIT	Advanced SM ^{1,2}			MAA	U.S.
		Non-advanced SM ¹				
	BLU-263: KIT	Non-advanced SM				
Genomically	AYVAKIT® (avapritinib): PDGFRA	PDGFRA GIST ^{1,3,4}				U.S., Europe
defined cancers	GAVRETO® (pralsetinib): RET	RET+ NSCLC ^{1,3,5,6}				U.S., Europe
		RET+ thyroid cancer ^{1,3,5,7}			MAA	U.S.
		Other RET+ solid tumors ^{1,3,5}	i.			
	BLU-701: EGFR	EGFR+ NSCLC ^{3,8}				
	BLU-945: EGFR	EGFR+ NSCLC ^{3,8}				ongoing or completed
	BLU-451: EGFR exon 20 insertions	EGFR+ NSCLC ³				planned
_	BLU-222: CDK2	Cyclin E aberrant cancers				
Cancer immunotherapy	BLU-852: MAP4K1	Advanced cancers ⁹				
)	Multiple undisclosed research programs					

1. CStone Pharmaceuticals has exclusive rights to develop and commercialize avapritinib, pralselinib and fisogatinib in Mainland China, Hong Kong, Macau and Taiwan. 2. Approved in the U.S. for the treatment of adults with advanced SM, including aggressive SM, SM with an associated hematologic neoplasm and mast cell leukemia. Received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for the treatment of adult patients with agressive SM, SM with an associated hematological neoplasm or metastatic Gist in European Medicines Agency's Committee for Medicinal Products for Human Use for the treatment of adult patients with agressive SM, SM with an associated hematological neoplasm or metastatic Gist in European Medicines Agency's Committee for Medicinal Products for Human Use for the treatment of adult patients with agressive SM, SM with an associated hematological neoplasm or metastatic Gist harboring the PDGFRA D842V mutations. For come the treatment of adults with advanced KT fusion-positive through a DGFRA D842V mutation. S. In collaboration with Roche. Blueprint Medicines and Roche have co-exclusive rights to develop and commercialize pralsetinib outside the U.S., excluding the CStone territory. 6. Received conditional marketing authorization in the U.S. for the treatment of adults with advanced KT fusion-positive through accelerated approval in the U.S. for the treatment of adults with advanced Agence and RET fusion-positive through accelerated approval in the U.S. for the treatment of adults with advanced Agence and RET fusion-positive through accelerated approval in the U.S. for the treatment of adults with advanced Agence and RET fusion-positive through accelerated approval in the U.S. for the treatment of adults with advanced Agence and RET fusion-positive through accelerated approval in the U.S. for the treatment of adults with advanced Agence and RET fusion-positive through accelerated approval in the U.S. for the treatment of adults with advanced Agence



Blueprint Medicines, AYVAKIT, AYVAKYT, GAVRETO and associated logos are trademarks of Blueprint Medicines Corporation.

Strong financial position bolstered by diversity of revenue & growing product revenue

Statement of Operations (unaudited)	Three Months Ended 12/31/2021	Three Months Ended 12/31/2020	FY Ended 12/31/2021	FY Ended 12/31/2020
Total revenue	\$107.0M	\$34.1M	\$180.1M	\$793.7M
Net product sales Collaboration revenue	\$20.M \$87.0M	\$6.7M \$27.4M	\$57.7M \$122.4M	\$22.1M \$771.6M
Cost of sales	\$7.5M	\$0.1M	\$17.9M	\$0.4M
Collaboration loss sharing	\$4.5M		\$7.8M	
Research & development expense ^{1,2}	\$356.9M	\$77.4M	\$601.0M	\$326.9M
Selling, general & admin expense ³	\$54.2M	\$42.5M	\$195.3M	\$157.7M
Net income (loss)	\$(318.7)M	\$(85.7)M	\$(644.1)M	\$313.9M
Balance Sheet (unaudited)	12/31/2021	12/31/2020		
Cash, cash equivalents and investments	\$1,034.6M	\$1,549.7M		

ANTICIPATE \$180 TO \$200 MILLION IN TOTAL NET REVENUES IN 2022



1. Includes stock-based compensation expense of \$10.0M and \$8.5M in the three months ended 12/31/21 and 12/31/20, respectively, and \$39.7M and \$33.6M in the full year ended 12/31/21 and 12/31/20, respectively. 2. Includes a one-time charge of \$260.0M to acquire in-process research and development compounds through the acquisition of Lengo Therapeutics. 3. Includes stock-based compensation expense of \$12.7M and \$11.0M in the three months ended 12/31/21 and 12/31/20, respectively, and \$52.0 and \$41.9M in the full year ended 12/31/21 and 12/31/20.

Our path to potential transformative growth and an independent financial profile

YEAR END 2021

- AYVAKIT/AYVAKYT and GAVRETO approved with ongoing global expansion
- A leading precision therapy research platform
- Strong financial position with ~\$1B cash and cash equivalents

NEAR-TERM PLANS

- Constellation of clinical across strategic therape
- AYVAKIT launch in non systemic mastocytosis
- Continued product reve collaboration milestones

FUTURE GOALS • 2024-2025+

- Broad portfolio of marketed medicines in precision oncology and hematology
- Diversified research platform with unparalleled productivity
- Independent financial profile

